ArQule (NASDAQ:ARQL) issued an update on its FY 2019 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $-0.37–0.35 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $-0.38. The company issued revenue guidance of $3-5 million, compared to the consensus revenue estimate of $4.25 million.
Shares of NASDAQ ARQL traded down $0.01 during trading hours on Friday, hitting $9.25. 1,080,273 shares of the stock were exchanged, compared to its average volume of 1,597,202. The company has a quick ratio of 6.45, a current ratio of 6.45 and a debt-to-equity ratio of 0.17. The business’s 50 day moving average is $10.56. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of -57.81 and a beta of 2.22. ArQule has a one year low of $2.23 and a one year high of $12.22.
ArQule (NASDAQ:ARQL) last released its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. The firm had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $1.43 million. ArQule had a negative net margin of 349.34% and a negative return on equity of 42.19%. During the same period in the prior year, the company earned $0.05 EPS. On average, analysts anticipate that ArQule will post -0.37 EPS for the current year.
In other ArQule news, Director Ran Nussbaum acquired 307,692 shares of the company’s stock in a transaction dated Thursday, June 27th. The stock was bought at an average price of $9.75 per share, for a total transaction of $2,999,997.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 13.80% of the stock is owned by corporate insiders.
ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer.
Further Reading: How a Back-End Load Mutual Fund Works
Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.